Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $165 from $160 and keeps an Overweight rating on the shares. While data readouts have played out in Q1, the firm expects Axsome to remain attractive for its commercial execution and underappreciated pipeline. Wells continues to see growth drivers in Auvelity performance, Symbravo launch, and detailed AD agitation data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead
- Axsome Therapeutics: Strong Growth Potential with Auvelity’s Market Expansion and Strategic Initiatives
- Axsome Therapeutics Reports Strong Q1 2025 Growth
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges
- Morning Movers: Skechers surges following take-private deal